home / stock / lxrx / lxrx news


LXRX News and Press, Lexicon Pharmaceuticals Inc. From 07/28/22

Stock Information

Company Name: Lexicon Pharmaceuticals Inc.
Stock Symbol: LXRX
Market: NASDAQ
Website: lexpharma.com

Menu

LXRX LXRX Quote LXRX Short LXRX News LXRX Articles LXRX Message Board
Get LXRX Alerts

News, Short Squeeze, Breakout and More Instantly...

LXRX - Lexicon Announces Pricing of $85.0 Million Public Offering and Concurrent Private Placement

THE WOODLANDS, Texas, July 28, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced the pricing of its previously announced underwritten public offering of 16,843,600 shares of its common stock, par value $0.001 (the ...

LXRX - Lexicon Pharmaceuticals stock slides on proposed stock offering

Lexicon Pharmaceuticals ( NASDAQ: LXRX ) shares dipped 16% in extended session after the biopharmaceutical company proposed an underwritten public offering of common stock. Lexicon intends to grant the underwriters a 30-day option to purchase additional shares of the s...

LXRX - Lexicon Announces Proposed Public Offering Of Common Stock

THE WOODLANDS, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stoc...

LXRX - Lexicon announces FDA review of heart failure therapy

Clinical-stage biotech Lexicon Pharmaceuticals ( NASDAQ: LXRX ) announced on Wednesday that the FDA accepted its New Drug Application (NDA) for sotagliflozin, an experimental therapy targeted at heart failure. The regulator has granted a standard review for the NDA with a PDUF...

LXRX - Lexicon Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure

THE WOODLANDS, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review and filed its New Drug Application (NDA) for sotagliflozin, an investigational dual SGLT1 and SGL...

LXRX - Lexicon Pharmaceuticals: Encouraging Signs Of Efficacy In Pain, But Still Looking For A Clear Win

Lexicon's Phase II proof-of-concept study in diabetic neuropathy delivered some encouraging signs of efficacy, but more data and potentially further dose optimization work are needed. Pain is a significant commercial opportunity for Lexicon, but it will likely need a partner to maximi...

LXRX - LXRX, AVDL and HHS among mid-day movers

Gainers: Rubicon Technology ( RBCN ) +68% . Faraday Future Intelligent Electric ( FFIE ) +65% . Ra Medical Systems ( RMED ) +61% . Xilio Therapeutics ( XLO ) +35% . Maris-Tech ( MTEK ) +35% . Lexicon Pharmaceuticals ( LXRX ...

LXRX - PSTG, LXRX and CANO are among pre market gainers

Perimeter Solutions ( PRM ) +38% . Compute Health Acquisition ( CPUH ) +12% . Cano Health ( CANO ) +12% . Lexicon Pharmaceuticals ( LXRX ) +6% . Pure Storage ( PSTG ) +6% . For further details see: PSTG, LXRX and CANO a...

LXRX - ArcelorMittal, Universal Health Services, RH among premarket losers' pack

Renalytix ( RNLX ) -28% on Q3 earnings release . Angion Biomedica ( ANGN ) -27% after it discontinued phase 2 trial of ANG-3070 in patients with kidney disease . Exicure ( XCUR ) -23% as it implements reverse-stock-split to get back Nasdaq com...

LXRX - LXRX, ADAG, HYPR and CYTK among after hour movers

Gainers: Adagene ( ADAG ) +20.3 % . Qorvo ( QRVO ) +11.5% . Lexicon Pharmaceuticals ( LXRX ) +9.8% . Avadel Pharmaceuticals ( AVDL ) +9.0% . The RealReal ( REAL ) +7.3% . Losers: HyperFeed Technologies ( HYPR ) ...

Previous 10 Next 10